What Lavipharm does

Lavipharm S.A. is a Greek pharmaceutical group founded in 1911 and listed on the Athens Stock Exchange since 1995 (ticker: LAVPH), headquartered in Peania, Attica. The company develops, manufactures, and markets prescription pharmaceuticals spanning cardiology, neurology/CNS, urology, oncology, and chronic pain management, alongside OTC products, food supplements, and the Castalia dermocosmetic brand (Sensial, Dermopur, Chronoderm, Helioderm, Lavilon, Dermogiene). Its core technical differentiator is proprietary transdermal drug delivery technology, including Supercritical Fluid Technology developed through R&D centers in Greece, France, and the USA, with flagship products such as the fentanyl transdermal patch (Fentadur/Dolfen) approved in 21+ European countries and validated for U.S. production.

Lavipharm operates an integrated business model combining proprietary R&D, GMP-certified manufacturing, wholesale distribution via Lavipharm Active Services (LAS), and a captive pharmacy network (Pharma PLUS) covering 88+ pharmacies in Greece with a 105,000-member loyalty program. Domestically, products are sold exclusively through pharmacies. Internationally, the company monetizes its transdermal platform through licensing and export partnerships — notably with Pfizer Hellas (co-marketing of Dolfen in Greece), Chiesi (nitroglycerine transdermal system in Italy, generating €8.0 million in 2010), and Belgian Tilman (plant-based pharma distribution in Greece) — operating across 21+ European countries for pharmaceutical products and 13 countries for Castalia dermocosmetics. The Group also includes subsidiaries Lavipharm Hellas, Pharma Logistics, Castalia Laboratoires Dermatologiques, and LIFELAB CBD.

The revenue model is a hybrid of one-time product sales (prescription pharma, OTC, dermocosmetics), licensing/royalty income from transdermal technology, and distribution/wholesale services. Pricing is largely regulated by Greek and European pharmaceutical reimbursement frameworks. Following a turbulent period including the 2017 dissolution of the U.S. subsidiary Lavipharm Corp. (€14.3 million extraordinary gains) and the May 2021 death of longtime Executive Chairman and majority shareholder Athanase Lavidas, the company has stabilized; the Group announced its first dividend in 18 years (€0.02 per share) at the April 2025 Annual Analysts Briefing.

Name

Lavipharm

Legal name

Lavipharm S.A.

Website

https://lavipharm.com

Company type

Public

Founded year

1911

Operating status

Operating

Short description

Lavipharm is a Greek pharmaceutical company (founded 1911, Athens-listed) that develops, manufactures, and distributes prescription drugs, OTC products, and Castalia dermocosmetics through its own transdermal delivery technology, an 88+ pharmacy Pharma PLUS network, and licensing partnerships across 21+ European countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmacies and Drug Retailers (45611), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience) (CRAOAHAG), Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops) (CRAOAHAK), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Transdermal drug delivery
• Pharmaceutical manufacturing
• Dermocosmetic skincare products
• Pharmacy network operations
• Prescription pharmaceutical products

Headquarters

HQ city

Peania Attica

HQ country

Greece

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales (Prescription and OTC): Lavipharm generates revenue primarily from manufacturing and selling prescription pharmaceutical products covering cardiology, neurology/CNS, urology, oncology, and chronic pain, as well as OTC products and food supplements. Products are sold exclusively through pharmacies in Greece and internationally via exports. Therapeutic categories include asthma, dermatological, gastrointestinal, neurological, cardiological, general medicine, and pain management treatments.
2. Dermocosmetic Product Sales: Castalia Laboratoires Dermatologiques products (dermocosmetics) are sold exclusively in pharmacies across 13 countries. The portfolio includes skincare lines for sensitive skin, oily/acne-prone skin, anti-aging, sun protection, and hair/scalp care.
3. Licensing Out (International): Lavipharm licenses its proprietary transdermal delivery systems to international partners. Key agreements include co-marketing with Pfizer Hellas (fentanyl patch/Dolfen in Greece), distribution with Chiesi (nitroglycerine transdermal system in Italy), and exports of transdermal fentanyl systems to multiple international markets across 21+ European countries. In 2017, international sales of transdermal systems represented 34.1% of total turnover.
4. Pharmacy Network / Distribution Services: Lavipharm operates Lavipharm Active Services (LAS), a pharmaceutical wholesale and distribution operation, and Pharma PLUS, a network of 88+ affiliated pharmacies across Greece. These provide logistics, marketing, and sales services for pharmaceutical and consumer health products throughout the Greek market.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Lavipharm develops, manufactures, and markets pharmaceutical products including prescription medicines (cardiology, neurology, oncology, chronic pain), OTC products, food supplements, and the Castalia dermocosmetic range. The company specializes in proprietary transdermal drug delivery systems using Supercritical Fluid Technology, producing fentanyl patches (Fentadur/Dolfen) and nitroglycerine patches. It also operates the Pharma PLUS pharmacy network of 88+ affiliated pharmacies across Greece and provides pharmaceutical wholesale services through Lavipharm Active Services (LAS).

Product overview

Lavipharm is a dynamic, international healthcare company providing pharmaceutical, dermocosmetic, and consumer health products. The portfolio includes prescription pharmaceuticals across cardiology, neurology, urology, oncology, and chronic pain; OTC products; food supplements; and dermocosmetics under the Castalia brand (covering hydration, acne care, anti-aging, sun protection, and hair care). Key products include Algon analgesic, LACTAL vaginal gel, and Digestil herbal lozenges. Through the Pharma PLUS network and LAVINET technology platform, Lavipharm serves over 88 pharmacies across Greece. The company also distributes Belgian Tilman's plant-based pharmaceutical products including Thymo cold remedies, Calmiderm, and Elimin INTENSE supplements.

Differentiator

Problem solved

Functional benefit

Brands

• LIFELAB CBD: CBD product line under Lavipharm's products
• Castalia Laboratoires Dermatologiques
• Pharma PLUS
• SENSIAL
• Dermopur
• Chronoderm
• Helioderm
• Lavilon
• Dermogiene

Products and services

• Castalia Dermocosmetics Dermatological skincare product brand offering clinically tested lines for sensitive skin (Sensial), oily/acne-prone skin (Dermopur), anti-aging (Chronoderm), sun protection (Helioderm), hair/scalp care (Lavilon), and body hygiene (Dermogiene). Sold exclusively in pharmacies across 13 countries.
• Algon Pain relief analgesic combining acetylsalicylic acid (400mg), paracetamol (200mg), and caffeine (50mg) for headache, fever, arthralgia, toothache, neuralgia, myalgia, and dysmenorrhea.
• LACTAL Vaginal Gel

Quantifiable outcome

• Transdermal system exports represented 34.1% of total turnover in 2017, growing 27.2% vs 2016
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Lavipharm Active Services SAcoreOthers · 14 March 2019Lavipharm SA (parent company) participated in a €3.492 million share capital increase of its 100% subsidiary Lavipharm Active Services SA. The contribution was made in kind — Lavipharm SA contributed its entire participation in Pharma PLUS SA (another subsidiary) to Lavipharm Active Services SA, valued at €3.492 million by independent audit firm PKF Euro-Auditing SA. This restructured the ownership chain while maintaining 100% ownership through the subsidiary.
• Pfizer HellascoreChannel Partner/ Reseller/ Distributor · 1 January 2010Lavipharm entered a new cooperation with Pfizer for the co-marketing of its fentanyl transdermal patch (Dolfen) in the Greek market. Pfizer Hellas promotes the product through its sales force while it is marketed under Lavipharm's trademark Dolfen. Lavipharm had been marketing the same product in Greece since 2007 under the brand Fentadur. Both brands continue to be distributed under Lavipharm-owned trademarks.
• ChiesicoreChannel Partner/ Reseller/ Distributor · 1 January 2010Lavipharm entered an agreement with Italian pharmaceutical company Chiesi for the nitroglycerine transdermal system covering the Italian market. The agreement generated extraordinary income of €8.0 million for Lavipharm in 2010. In Italy, Lavipharm also maintains supply and distribution agreements with two additional companies that distribute the product under Lavipharm-owned trademarks. Italy represents the most significant market for this specific product.
• TilmancoreChannel Partner/ Reseller/ DistributorLavipharm entered a cooperation agreement with Belgian medical plant specialist Tilman for the distribution of plant-based pharmaceutical products in Greek pharmacies. Tilman is one of the largest such companies in Europe with products marketed in 30 countries. Products distributed include Digestil (indigestion), Thymo line (cold/flu), Tilman Elimin Intense (slimming), Calmiderm (skin irritation), and Tilman Junior Eucalyptus (respiratory for children). Phytotherapy represents an emerging market segment in Greece, and Lavipharm positioned this as a strategic investment in a promising category with a well-established partner.

Scale indicators7 records

Recent moves10 records

Expansion highlights5 records

Broad incumbents

• Teva Pharmaceutical Industries: Global leader in generic and specialty pharmaceuticals with significant transdermal patch franchise. Comparable in transdermal drug delivery technology positioning and broad generic/specialty portfolio across pain management and CNS.
• Viatris: Global pharmaceutical company formed from the Mylan-Upjohn combination, with a leading generics portfolio and significant branded specialty franchise. Comparable in transdermal and pain management product overlap and broad pharmacy-channel distribution.
• Menarini Group: Italy's largest pharmaceutical company with a broad branded specialty portfolio, OTC consumer health brands and international presence. Comparable as a Southern European integrated pharma group with pharmacy-channel distribution and OTC/specialty diversification.
• Almirall: Spanish specialty pharmaceutical company focused on dermatology and specialty care with European commercial footprint. Comparable to Lavipharm's Castalia dermocosmetic franchise and specialty pharma orientation.
• Recordati: Italian mid-cap specialty pharmaceutical group with proprietary products in cardiovascular, urology and rare diseases and a wide European distribution network. Comparable in therapeutic area overlap (cardiology, urology) and European specialty pharma positioning.
• Chiesi Farmaceutici: Italian specialty pharmaceutical company operating in respiratory, neonatology and rare diseases with global licensing partnerships. Comparable as a partner of Lavipharm (nitroglycerine transdermal licensee) and as a European specialty pharma peer with similar branded specialty positioning.

Direct peers

• Help Pharmaceuticals: Greek pharmaceutical company marketing branded generics and consumer health products through Greek pharmacies. Closely comparable in product mix (Rx + OTC + supplements) and exclusive pharmacy distribution strategy within Greece.
• DEMO SA: Greek pharmaceutical manufacturer specializing in injectable hospital products and generics with significant export footprint across 85+ countries. Comparable to Lavipharm as a fellow Greek integrated pharma group with manufacturing, R&D, and international licensing operations.
• ELPEN Pharmaceutical: One of the largest Greek pharmaceutical manufacturers, focused on branded generics and specialty therapeutics sold through Greek pharmacies. Closely comparable to Lavipharm in scale, channel (pharmacy-exclusive), and therapeutic area breadth across respiratory, cardiovascular and CNS categories.
• Pharmathen: Greek-based specialty pharmaceutical company focused on generic and value-added formulations with strong R&D and global licensing. Comparable to Lavipharm's branded specialty franchise, international licensing-out model, and Greek manufacturing footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Lavipharm
• LinkedInlinkedin.com/company/lavipharm

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lavipharm